In vitro, internalization of DM001 bsAb into a TROP2+EGFR+ cell line is comparable with that of its parental monoclonal anti-TROP2 or anti-EGFR antibodies. Tumor killing of double positive cell lines is also comparable between DM001 and its parental ADCs....Importantly, DM001 demonstrated strong anti-tumor activity in several cell line-derived and patient-derived xenografts, including lung and pancreatic tumors. Notably, the efficacy of DM001 was superior to benchmark ADCs in A431 and Panc.02.03 xenografts. Interestingly, the efficacy of DM001 was superior to its parental ADCs in BP0508 lung cancer and BP0209 pancreatic cancer PDX models...DM001 is a novel bispecific ADC with promising therapeutic potential that can be further exploited to treat TROP2 and EGFR co-expressing tumors.